Pharmaceutical composition and dosage form comprising dronedarone, and preparation method thereof

Abstract

The disclosure relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in unit dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal time effect following oral administration in humans. The lipid carrier allows: the solubilization of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising at least one active principle selected from (i) 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran in the form of base and (ii) 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran in the form of a pharmaceutically acceptable salt; and at least one amphiphilic lipid excipient with HLB value between 2 and 20. 
     
     
         2 . The composition according to  claim 1 , wherein the 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran in the form of a pharmaceutically acceptable salt is selected from 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran hydrochloride, 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran fumarate and 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran oxalate. 
     
     
         3 . The composition according to  claim 1 , wherein the active principle is selected from 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran in the form of base and 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran hydrochloride. 
     
     
         4 . The composition according to  claim 1 , wherein said composition further comprises at least one surfactant and/or at least one co-solvent. 
     
     
         5 . The composition according to  claim 1 , wherein said amphiphilic lipid excipient with HLB value between 2 and 20 has a melting point below 50° C. 
     
     
         6 . The composition according to  claim 1 , wherein said lipid excipient is selected from the semi-solid substituted glycerides, the liquid substituted glycerides, the semi-solid substituted polyoxylglycerides, the liquid substituted polyoxylglycerides and mixtures thereof. 
     
     
         7 . The composition according to  claim 1 , wherein said lipid excipient is selected from the Gelucires marketed under the brand name Gelucire® 33/01, Gelucire® 39/01, Gelucire® 43/01, Geleol® and Peceol™, the glycerides marketed under the name Labrafac Lipophile® WL1349, the Gelucires marketed under the brand name Gelucire®44/14 and Gelucire®50/13, the polyoxylglycerides marketed under the brand name Labrafir®M1944CS, Labrafir®M2125CS, Labrafir®M2130CS and Labrasol®, the medium-chain mono- and diglycerides marketed under the name Capmul MOM®, propylene glycol monolaurate marketed under the name Lauroglycol® 90 and Capmul PG12®, the caprylocaproyl macrogol-8 glycerides marketed under the name Labrasol®, the propylene glycol caprylic acid monoester marketed under the name Capmul® PG-8 and mixtures thereof. 
     
     
         8 . The composition according to  claim 1 , wherein said lipid excipient is selected from the lipid excipients having an HLB value between 5 and 18. 
     
     
         9 . The composition according to  claim 8 , wherein said lipid excipient is selected from the lipid excipients sold under the trade name Capmul MOM®, Lauroglycol® 90, Capmul PG12®, Labrasol®, Gelucire® 44/14, Gelucire®50/13 and Capmul® PG-8. 
     
     
         10 . The composition according to  claim 1 , comprising 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran hydrochloride, as active principle and/or at least one semi-solid substituted polyoxylglyceride as lipid excipient. 
     
     
         11 . The composition according to  claim 1 , comprising:
 1-60 wt % of at least one active principle;   40-99 wt % of at least one lipid excipient; and   0-30% of at least one compound selected from surfactants, co-solvents, diluents, disintegrants, lubricants, organic or inorganic bases and plasticizers,   
       the percentages being expressed by weight relative to the total weight of said composition. 
     
     
         12 . The composition according to  claim 1 , comprising:
 1-60 wt % of at least one active principle;   40-99 wt % of at least one lipid excipient,   0-30 wt % of at least one surfactant, and   0-29 wt % of at least one co-solvent;   
       the percentages being expressed by weight relative to the total weight of said composition. 
     
     
         13 . The composition according to  claim 12 , comprising:
 1-50 wt % of at least one active principle;   45-80 wt % of at least one lipid excipient;   1-20 wt % of at least one surfactant; and   1-20 wt % of at least one co-solvent.   
     
     
         14 . The composition according to  claim 12 , wherein the surfactant is hydrophilic and nonionic. 
     
     
         15 . The composition according to  claim 12 , wherein the surfactant is selected from:
 ethylene oxide/propylene oxide copolymers;   polyethoxylated castor oils;   ethoxylated polysorbates, and   polyethylene hydroxystearates.   
     
     
         16 . The composition according to  claim 12 , wherein the surfactant is poloxamer 407. 
     
     
         17 . The composition according to  claim 12 , wherein the co-solvent is selected from the alcoholic organic solvents and the glycol derivatives. 
     
     
         18 . A dosage form comprising a composition according to  claim 1 . 
     
     
         19 . The dosage form according to  claim 18 , which is in the form of a capsule selected from hard capsules, soft shell capsules, enteric capsules and modified-release capsules. 
     
     
         20 . The dosage form according to  claim 19 , which is in the form of a hard capsule. 
     
     
         21 . The dosage form according to  claim 18 , comprising between 50 and 500 mg of active principle. 
     
     
         22 . The dosage form according to  claim 18 , comprising between 200 and 400 mg of active principle.